The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model

The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model

Therapeutic regimens for chronic lymphocytic leukemia (CLL) have increasingly utilized monoclonal antibodies since the chimeric anti-CD20 antibody rituximab was introduced. Despite improved clinical outcomes, current CLL therapies are not curative. Therefore, antibodies with greater efficacy and nov...

Full description

Bibliographic Details
Main Authors: Beckwith, Kyle A., Frissora, Frank W., Stefanovski, Matthew R., Towns, William H., Cheney, Carolyn, Mo, Xiaokui, Deckert, Jutta, Croce, Carlo M., Flynn, Joseph M., Andritsos, Leslie A., Jones, Jeffrey A., Maddocks, Kami J., Lozanski, Gerard, Byrd, John C., Muthusamy, Natarajan
Format: Online
Language:English
Published: 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090271/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090271/

Similar Items